Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Acute Effects of an Orally Active Dopamine Prodrug (TA-870) on Systemic Haemodynamics and Renal Functions

  • 3 Accesses

  • 1 Citations


The acute haemodynamic and renal effects of TA-870, an orally active dopamine prodrug, were investigated in 30 patients with coronary artery disease. Haemodynamic and renal effects of TA-870 were determined following Swan-Ganz catheterisation and clearance tests, respectively, for 4 hours after the administration of 750, 1050 and 1500mg doses.

TA-870 significantly increased cardiac index (6 to 13%) and stroke volume index (8 to 11%) but significantly decreased systemic vascular resistance (8 to 15%) 1 to 2 hours after administration, while causing no significant change in heart rate, mean blood pressure, right atrial pressure, mean pulmonary artery pressure, left ventricular stroke work index, total pulmonary resistance and oxygen consumption. TA-870 significantly increased urine volume (39 to 51%), renal blood flow (27 to 93%), glomerular filtration rate (18 to 52%) and urinary electrolyte excretion (Na, 27 to 214%; Cl, 26 to 259%).

The systemic haemodynamic and renal effects of TA-870 were similar to those obtained by the continuous infusion of low dose dopamine. There were no adverse effects at any dose levels tested. Thus, orally administered TA-870 warrants further investigation as a practical alternative to low-dose dopamine infusion.

This is a preview of subscription content, log in to check access.


  1. Chernow B, Rainey TG, Lake CR. Endogenous and exogenous catecholamines in critical care medicine. Critical Care Medicine 10: 409–416, 1982

  2. Dasta JF, Kirby MG. Pharmacology and therapeutic use of lowdose dopamine. Pharmacotherapy 6: 304–310, 1986

  3. Davis RF, Lappas DG, Kirklin JK, Buckley MJ, Lowenstein E. Acute oliguria after cardiopulmonary bypass: renal functional improvement with low-dose dopamine infusion. Critical Care Medicine 10: 852–856, 1982

  4. D’orio V, EI Allaf D, Juchmes J, Marcelle R. The use of low doses of dopamine in intensive care medicine. Archives of Internal Physiology and Biochemistry 92: S11–S20, 1984

  5. Ferrini R, Miragoli G. Activity of ibopamine on some isolated organs. Arzneimittel-Forschung 36: 312–317, 1986

  6. Goldberg LI. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacological Reviews 24: 1–29, 1972

  7. Goldberg LI. Dopamine: clinical uses of an endogenous catecholamine. New England Journal of Medicine 219: 707–710, 1974

  8. Goldberg LI. Dopamine: receptors and clinical applications. Clinical Physiology and Biochemistry 3: 120–126, 1985

  9. Goldberg LI, Mcdonald RH, Zimmerman AM. Sodium diuresis produced by dopamine in patients with congestive heart failure. New England Journal of Medicine 268: 1060–1064, 1963

  10. Hashizume K, Yamatodani A, Yamamoto T, Ogihara T, Kumahara Y, et al. Effects of oral and intravenous administrations of dopamine and L-DOPA on plasma levels of two isomers of dopamine sulfate in man. Life Sciences 41: 2697–2704, 1987

  11. Linder A. Synergism of dopamine and furosemide in diuretic-resistant, oliguric renal failure. Nephron 37: 39–42, 1983

  12. Melloni GF, Minoja GM, Lureti GF, et al. Effects of SB7505 on blood pressure, heart rate and diuresis in man. Current Therapeutic Research 25: 406–414, 1979

  13. Melloni GF, Minoja GM, Scorazzati G, et al. Renal effects of SB7505: double-blind study. European Journal of Clinical Pharmacology 19: 177–180, 1981

  14. Sannia L, Ibba GV, Gastellaccio M, et al. Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure. Arzneimittel-Forschung 36: 355–359, 1986

  15. Smith HW, Finkelstein N, Aliminosa L, et al. The renal clearances of substituted hippuric acid derivatives and other aromatic acid in dog and man. Journal of Clinical Investigation 24: 388–404, 1945

  16. Stefoni S, Coli L, Mosconi G, et al. Ibopamine (SB7505) in normal subjects and in chronic renal failure: a preliminary report. British Journal of Clinical Pharmacology 1: 69–72, 1981

  17. Tanimura C, Kitagawa Y, Fukui T, et al. Plasma free dopamine levels and clinical effects following oral administration of dopamine prodrug (TA-870). Japanese Journal of Acute Medicine 9: 473–479, 1985

  18. Ventura HO, Messerli FH, Frohlich ED, et al. Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension. Circulation 69: 1142–1145, 1984

  19. Wee PM, Smit AJ, Rosman JB, et al. Effect of intravenous infusion of low-dose dopamine on renal function in normal individuals and in patients with renal disease. American Journal of Nephrology 6: 42–46, 1986

  20. Yoshikawa M, Endo H, Komatsu K, et al. Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. Drug Metabolism and Disposition 18: 212–217, 1990

Download references

Author information

Correspondence to Dr Susumu Nishizaki.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nishizaki, S., Fukuma, A., Ogurusu, C. et al. Acute Effects of an Orally Active Dopamine Prodrug (TA-870) on Systemic Haemodynamics and Renal Functions. Drug Invest. 3, 118–125 (1991). https://doi.org/10.1007/BF03259551

Download citation


  • Dopamine
  • Cardiac Index
  • Pulmonary Artery Pressure
  • Renal Blood Flow
  • Pulmonary Capillary Wedge Pressure